Literature DB >> 29281104

Antigenic Characterization of a Novel Recombinant GII.P16-GII.4 Sydney Norovirus Strain With Minor Sequence Variation Leading to Antibody Escape.

Lisa C Lindesmith1, Paul D Brewer-Jensen1, Michael L Mallory1, Kari Debbink2, Excel W Swann1, Jan Vinjé3, Ralph S Baric1.   

Abstract

Background: Human noroviruses are the leading cause of acute gastroenteritis. Strains of the GII.4 genotype cause pandemic waves associated with viral evolution and subsequent antigenic drift and ligand-binding modulation. In November 2015, a novel GII.4 Sydney recombinant variant (GII.P16-GII.4 Sydney) emerged and replaced GII.Pe-GII.4 Sydney as the predominant cause of acute gastroenteritis in the 2016-2017 season in the United States.
Methods: Virus-like particles of GII.4 2012 and GII.4 2015 were compared for ligand binding and antibody reactivity, using a surrogate neutralization assay.
Results: Residue changes in the capsid between GII.4 2012 and GII.4 2015 decreased the potency of human polyclonal sera and monoclonal antibodies. A change in epitope A resulted in the complete loss of reactivity of a class of blockade antibodies and reduced levels of a second antibody class. Epitope D changes modulated monoclonal antibody potency and ligand-binding patterns. Conclusions: Substitutions in blockade antibody epitopes between GII.4 2012 and GII.4 2015 influenced antigenicity and ligand-binding properties. Although the impact of polymerases on fitness remains uncertain, antigenic variation resulting in decreased potency of antibodies to epitope A, coupled with altered ligand binding, likely contributed significantly to the spread of GII.4 2015 and its replacement of GII.4 2012 as the predominant norovirus outbreak strain.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29281104      PMCID: PMC5939617          DOI: 10.1093/infdis/jix651

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review.

Authors:  Rishi Desai; Christal D Hembree; Andreas Handel; Jonathan E Matthews; Benjamin W Dickey; Sharla McDonald; Aron J Hall; Umesh D Parashar; Juan S Leon; Benjamin Lopman
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

2.  Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Authors:  Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 3.  Noroviruses: epidemiology, immunity and prospects for prevention.

Authors:  Kimberly Pringle; Benjamin Lopman; Everardo Vega; Jan Vinje; Umesh D Parashar; Aron J Hall
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

4.  Genetic and Epidemiologic Trends of Norovirus Outbreaks in the United States from 2013 to 2016 Demonstrated Emergence of Novel GII.4 Recombinant Viruses.

Authors:  Jennifer L Cannon; Leslie Barclay; Nikail R Collins; Mary E Wikswo; Christina J Castro; Laura Cristal Magaña; Nicole Gregoricus; Rachel L Marine; Preeti Chhabra; Jan Vinjé
Journal:  J Clin Microbiol       Date:  2017-05-10       Impact factor: 5.948

5.  Re-emergence of a GII.4 Norovirus Sydney 2012 Variant Equipped with GII.P16 RdRp and Its Predominance over Novel Variants of GII.17 in South Korea in 2016.

Authors:  Yong Seon Choi; Eung Seo Koo; Man Su Kim; Jong Duck Choi; Yongsik Shin; Yong Seok Jeong
Journal:  Food Environ Virol       Date:  2017-01-24       Impact factor: 2.778

6.  Emergence of a novel GII.17 norovirus – End of the GII.4 era?

Authors:  M de Graaf; J van Beek; H Vennema; A T Podkolzin; J Hewitt; F Bucardo; K Templeton; J Mans; J Nordgren; G Reuter; M Lynch; L D Rasmussen; N Iritani; M C Chan; V Martella; K Ambert-Balay; J Vinjé; P A White; M P Koopmans
Journal:  Euro Surveill       Date:  2015-07-02

7.  The Evolution and Transmission of Epidemic GII.17 Noroviruses.

Authors:  Jing Lu; Lin Fang; Huanying Zheng; Jiaqian Lao; Fen Yang; Limei Sun; Jianpeng Xiao; Jinyan Lin; Tie Song; Tao Ni; Jayna Raghwani; Changwen Ke; Nuno R Faria; Thomas A Bowden; Oliver G Pybus; Hui Li
Journal:  J Infect Dis       Date:  2016-05-24       Impact factor: 5.226

8.  Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Authors:  Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric
Journal:  PLoS Pathog       Date:  2012-05-17       Impact factor: 6.823

9.  Analysis of amino acid variation in the P2 domain of the GII-4 norovirus VP1 protein reveals putative variant-specific epitopes.

Authors:  David J Allen; Jim J Gray; Chris I Gallimore; Jacqueline Xerry; Miren Iturriza-Gómara
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

10.  Emergence of new norovirus strain GII.4 Sydney--United States, 2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-01-25       Impact factor: 17.586

View more
  19 in total

1.  Antigenic Site Immunodominance Redirection Following Repeat Variant Exposure.

Authors:  Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Mark R Zweigart; Samantha R May; Daniel Kelly; Rachel Williams; Sylvia Becker-Dreps; Filemón Bucardo; David J Allen; Judith Breuer; Ralph S Baric
Journal:  Viruses       Date:  2022-06-14       Impact factor: 5.818

2.  Prevalence and genetic diversity of norovirus genogroup II in children less than 5 years of age with acute gastroenteritis in Tehran, Iran.

Authors:  Mahsa Farsi; Fatemeh Roodbari; Behrooz Nejati; Arash Arashkia; Somayeh Jalilvand; Alireza Nateghian; Aliakbar Rahbarimanesh; Sayed Mahdi Marashi; Zabihollah Shoja
Journal:  Med Microbiol Immunol       Date:  2018-04-04       Impact factor: 3.402

Review 3.  Human Norovirus Proteins: Implications in the Replicative Cycle, Pathogenesis, and the Host Immune Response.

Authors:  Claudia P Campillay-Véliz; Jonatan J Carvajal; Andrea M Avellaneda; Darling Escobar; Camila Covián; Alexis M Kalergis; Margarita K Lay
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

Review 4.  The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics.

Authors:  Jessica M van Loben Sels; Kim Y Green
Journal:  Viruses       Date:  2019-05-10       Impact factor: 5.048

Review 5.  GII.4 Human Norovirus: Surveying the Antigenic Landscape.

Authors:  Michael L Mallory; Lisa C Lindesmith; Rachel L Graham; Ralph S Baric
Journal:  Viruses       Date:  2019-02-20       Impact factor: 5.048

6.  Population Genomics of GII.4 Noroviruses Reveal Complex Diversification and New Antigenic Sites Involved in the Emergence of Pandemic Strains.

Authors:  Kentaro Tohma; Cara J Lepore; Gabriel I Parra; Yamei Gao; Lauren A Ford-Siltz
Journal:  mBio       Date:  2019-09-24       Impact factor: 7.867

7.  Humoral and Mucosal Immune Responses to Human Norovirus in the Elderly.

Authors:  Veronica P Costantini; Emilie M Cooper; Hope L Hardaker; Lore E Lee; Emilio E DeBess; Paul R Cieslak; Aron J Hall; Jan Vinjé
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

8.  Virus-Host Interactions Between Nonsecretors and Human Norovirus.

Authors:  Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Kara Jensen; Boyd L Yount; Veronica Costantini; Matthew H Collins; Caitlin E Edwards; Timothy P Sheahan; Jan Vinjé; Ralph S Baric
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-04-11

9.  Recombinant GII.P16/GII.4 Sydney 2012 Was the Dominant Norovirus Identified in Australia and New Zealand in 2017.

Authors:  Jennifer H Lun; Joanne Hewitt; Grace J H Yan; Daniel Enosi Tuipulotu; William D Rawlinson; Peter A White
Journal:  Viruses       Date:  2018-10-09       Impact factor: 5.048

10.  Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands.

Authors:  Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Boyd Yount; Matthew H Collins; Kari Debbink; Rachel L Graham; Ralph S Baric
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.